Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma

Published:2023-10-26 Issue:1 Volume:13 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Ludvigsen Maja^ORCID,Campbell Amanda Jessica^ORCID,Enemark Marie Beck,Hybel Trine Engelbrecht,Karjalainen-Lindsberg Marja-Liisa,Beiske Klaus,Bjerre Mette,Pedersen Lars Møller,Holte Harald,Leppä Sirpa^ORCID,Jørgensen Judit Meszaros,Honoré Bent^ORCID

Funder

Karen Elise Jensens Fond

Institut for Klinisk Medicin, Aarhus Universitet

A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

https://www.nature.com/articles/s41408-023-00931-6.pdf

Reference15 articles.

1. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet [Internet]. 2012;380:848–57. https://doi.org/10.1016/S0140-6736(12)60605-9.

2. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.

3. Longo DL, Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384:842–58.

4. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8.

5. Alizadeh AA, Elsen MB, Davis RE, Ma CL, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.